Sofosbuvir plus velpatasvir effective at treating HCV genotype 1 and 3 patients

Patients with genotype 1 or 3 hepatitis C virus (HCV) infection responded well to therapy with 400 mg of sofosbuvir combined with 100 mg of velpatasvir for 12 weeks, in a randomized, phase II,...